
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4097843/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 460-469.	6.4	36
2	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 71-78.	3.9	19
3	[68Ca]Ca-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1101-1112.	6.4	25
4	68Ga–Prostate-Specific Membrane Antigen–Avid Malignant Pleural Effusion in a Patient With Metastatic Adenoid Cystic Carcinoma and Concordance With 18F-FDG PET/CT. Clinical Nuclear Medicine, 2022, 47, 140-141.	1.3	1
5	PET imaging in thyroid cancer. , 2022, , .		ο
6	Research Highlight: ⁶⁸ Ga-PSMA-11 PET Imaging for Pelvic Nodal Metastasis in Prostate Cancer. Korean Journal of Radiology, 2022, 23, 293.	3.4	5
7	Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy – A German position paper from Surgery and Nuclear Medicine. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.7	7
8	Ferumoxtran-10-enhanced 3-T Magnetic Resonance Angiography of Pelvic Arteries: Initial Experience. European Urology Focus, 2022, 8, 1802-1808.	3.1	5
9	89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2064-2076.	6.4	22
10	An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging. Cancers, 2022, 14, 2076.	3.7	1
11	An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. Frontiers in Nuclear Medicine, 2022, 2, .	1.2	2
12	Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study. Clinical Cancer Research, 2022, 28, 4194-4202.	7.0	28
13	[¹⁷⁷ Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial Journal of Clinical Oncology, 2022, 40, 5001-5001.	1.6	15
14	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer and Prostatic Diseases, 2021, 24, 423-430.	3.9	37
15	Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1211-1218.	6.4	23
16	Head-to-Head Comparison of ⁶⁸ Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. Journal of Nuclear Medicine, 2021, 62, 1258-1263.	5.0	26
17	Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in nonâ€medullary thyroid cancer. Cellular Oncology (Dordrecht), 2021, 44, 611-625.	4.4	8
18	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clinical Cancer Research, 2021, 27, 3595-3601.	7.0	53

#	Article	IF	CITATIONS
19	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. Practical Radiation Oncology, 2021, 11, 202-211.	2.1	13
20	Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. Endocrine-Related Cancer, 2021, 28, 391-402.	3.1	10
21	Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer. Cancers, 2021, 13, 4193.	3.7	5
22	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 729.e7-729.e16.	1.6	34
23	Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells <i>In Vitro</i> . In Vivo, 2021, 35, 721-729.	1.3	2
24	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials, 2021, 22, 768.	1.6	13
25	Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer, 2020, 20, 884.	2.6	32
26	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. Cancers, 2020, 12, 3756.	3.7	4
27	⁶⁸ Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics, 2020, 10, 2273-2283.	10.0	45
28	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 250-264.	0.7	4
29	Imaging of Differentiated Thyroid Cancer with Iodine-124 and F-18-FDG. , 2019, , 199-204.		0
30	Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2019, 60, 9-15.	5.0	45
31	<i>EIF1AX</i> and <i>RAS</i> Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. Cancer Discovery, 2019, 9, 264-281.	9.4	57
32	The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 235-252.	0.7	20
33	Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities. Nuclear Medicine Communications, 2018, 39, 457-464.	1.1	5
34	Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer. Journal of Nuclear Medicine, 2018, 59, 780-786.	5.0	14
35	Quantitative performance of 124I PET/MR of neck lesions in thyroid cancer patients using 124I PET/CT as reference. EJNMMI Physics, 2018, 5, 13.	2.7	14
36	Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer. Journal of Molecular Endocrinology, 2017, 59, R141-R154.	2.5	13

#	Article	IF	CITATIONS
37	lodine Symporter Targeting with ¹²⁴ 1/ ¹³¹ I Theranostics. Journal of Nuclear Medicine, 2017, 58, 34S-38S.	5.0	39
38	Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma. BMC Cancer, 2017, 17, 887.	2.6	16
39	Serum Thyroglobulin Doubling Time in Progressive Thyroid Cancer. Thyroid, 2016, 26, 1712-1718.	4.5	26
40	Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. European Journal of Radiology, 2016, 85, 459-465.	2.6	81
41	Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. Journal of Clinical Investigation, 2016, 126, 4119-4124.	8.2	102
42	Abstract 892: Functional characterization of EIF1AX mutations in thyroid cancer predicts for gain of function by increasing translational rate with concomitant derepression of upstream inputs from mTOR. , 2016, , .		0
43	Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer. Investigative Radiology, 2015, 50, 505-513.	6.2	84
44	Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany. Endocrine Practice, 2015, 21, 122-127.	2.1	19
45	Correlation of <i>BRAF</i> ^{<i>V600E</i>} Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸ F-FDG PET Study. Journal of Nuclear Medicine, 2015, 56, 662-667.	5.0	37
46	Impact of dual-energy CT prior to radioembolization (RE). Acta Radiologica, 2015, 56, 1293-1299.	1.1	5
47	Combined PET Imaging and Diffusion-Weighted Imaging of Intermediate and High-Risk Primary Prostate Carcinomas with Simultaneous [18F] Choline PET/MRI. PLoS ONE, 2014, 9, e101571.	2.5	26
48	Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome. Archives of Gynecology and Obstetrics, 2014, 290, 1023-1030.	1.7	35
49	Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy 124I PET/CT imaging. EJNMMI Physics, 2014, 1, 100.	2.7	17
50	Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 505-510.	6.4	76
51	Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis. Annals of Nuclear Medicine, 2014, 28, 405-410.	2.2	35
52	Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 79-88.	6.4	54
53	Assessment of Lesion Response in the Initial Radioiodine Treatment of Differentiated Thyroid Cancer Using ¹²⁴ I PET Imaging. Journal of Nuclear Medicine, 2014, 55, 1759-1765.	5.0	78
54	Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by ¹⁸ F-FDG PET: Feasibility of a Metabolic Grading System. Journal of Nuclear Medicine, 2014, 55, 1260-1266.	5.0	76

#	Article	IF	CITATIONS
55	Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. British Journal of Cancer, 2014, 110, 1155-1162.	6.4	42
56	Diagnosis of hyperfunctional thyroidn odules. Nuklearmedizin - NuclearMedicine, 2014, 53, 173-177.	0.7	16
57	Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI Research, 2013, 3, 82.	2.5	26
58	Spatial Reconstruction of Human Thyroid based on Ultrasound and CT Image Data Fusion. Biomedizinische Technik, 2013, 58 Suppl 1, .	0.8	2
59	18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. Nuklearmedizin - NuclearMedicine, 2013, 52, 198-203.	0.7	22
60	Ultrasound-Guided Fine-Needle Aspiration Biopsy of Clinically Suspicious Thyroid Nodules with an Automatic Aspirator: A Novel Technique. Thyroid, 2012, 22, 695-698.	4.5	1
61	Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by ¹⁸ F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials. Journal of Nuclear Medicine, 2012, 53, 1836-1846.	5.0	22
62	Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma. Clinical Nuclear Medicine, 2012, 37, 121-127.	1.3	115
63	Effects of Rosiglitazone on Radioiodine Negative and Progressive Differentiated Thyroid Carcinoma as Assessed by 124I PET/CT Imaging. Clinical Nuclear Medicine, 2012, 37, e47-e52.	1.3	26
64	Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies. Annals of Nuclear Medicine, 2012, 26, 723-729.	2.2	23
65	124I-PET/CT images of differentiated thyroid cancer patients. Nuklearmedizin - NuclearMedicine, 2012, 51, 213-216.	0.7	10
66	Estimation of tumour mass in patients with differentiated thyroid carcinoma using serum thyroglobulin. Nuklearmedizin - NuclearMedicine, 2012, 51, 217-222.	0.7	7
67	Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 852-863.	6.4	68
68	18F-fluoride PET/CT for bone scanning. Nuklearmedizin - NuclearMedicine, 2012, 51, 84-87.	0.7	8
69	Success rate of repeated fine needle aspiration biopsy of clinically suspicious thyroid nodules. Nuklearmedizin - NuclearMedicine, 2012, 51, 116-118.	0.7	4
70	Pioglitazone therapy in progressive differentiated thyroid carcinoma. Nuklearmedizin - NuclearMedicine, 2012, 51, 111-115.	0.7	14
71	Time Course of Tumor SUV in ¹⁸ F-FDG PET of Breast Cancer: Presentation of a Simple Model Using a Single Reference Point for Time Corrections of Tumor SUVs. Journal of Nuclear Medicine, 2011, 52, 18-23.	5.0	9
72	Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1862-1868.	6.4	36

#	Article	IF	CITATIONS
73	Comparison of FDC-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiologica, 2011, 52, 1009-1014.	1.1	71
74	Ultrasound-guided Fine Needle Aspiration Biopsy (FNAB) of suspicious thyroid nodules with an automatic aspirator: a novel technique. Thyroid, 0, , 120216081232002.	4.5	0